Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you take tirzepatide and use oral contraceptives, there is a specific action to take: add a non-oral method of contraception — such as condoms — for the first four weeks of treatment and for four weeks after each dose increase. This is because tirzepatide slows gastric emptying, which can reduce how reliably the pill is absorbed. The decision about which contraception works alongside your treatment is worth making deliberately, before you start, not as an afterthought. These are prescription-only medicines, and a clinician needs to assess your full picture before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide works partly by slowing how quickly food and liquid move from the stomach into the small intestine. That mechanism is central to how it reduces appetite. But the same effect applies to oral medicines taken at the same time, including the contraceptive pill.
Oral contraceptives are absorbed through the gut wall. When absorption is slower or less predictable, the plasma levels of the pill's hormones may not reach the concentrations they are designed to. In practice, this does not mean the pill stops working entirely, but it introduces enough uncertainty that UK clinical guidance treats it as a meaningful risk, particularly at the start of treatment and when the dose is increased.
Each dose increase effectively restarts the adjustment period. So the four-week protective window applies again at 5mg, again at 7.5mg, and so on through the titration schedule. If you tend to reach each new dose around the same time each month (or if a dose increase coincides with a holiday or a busy patch when it is easy to forget) it is worth planning your additional contraception well in advance, not on the day.
This information is drawn from NHS Inform Scotland's guidance on diabetes and weight-loss medication and the NHS England weight-management injections guidance.
The concern here is specific to oral contraceptives, tablets and pills that pass through the stomach and depend on gut absorption. Non-oral hormonal methods are not subject to the same mechanism. The coil (both hormonal and copper), the implant, the contraceptive patch, the injection and the hormonal IUS all deliver hormones directly or act locally; they bypass the gut entirely.
If you already use a contraceptive implant, you do not need to add an additional method when starting tirzepatide. The same applies to the hormonal coil. These methods are unaffected by changes in gastric emptying speed.
Condoms are the simplest additional method for people on the pill who want to cover the four-week window without switching method. They are also the method most likely to be immediately to hand. Your prescriber can discuss the options that suit your situation, what matters is that you have a plan before the first pen is used, not midway through the first month.
If you are unsure which category your contraception falls into, our guide to how Mounjaro affects birth control pills explains the absorption detail, and your prescriber or GP can advise on your specific method.
The four-week absorption window is the most time-sensitive issue, but it is not the only contraception consideration. MHRA guidance advises that women of childbearing age use effective contraception throughout treatment with tirzepatide, and for a period after stopping, before trying to conceive. Tirzepatide is not recommended in pregnancy, during breastfeeding, or in people who are actively trying to become pregnant.
This wash-out recommendation exists because tirzepatide's effects on the developing foetus have not been fully established in human studies. The prescriber reviewing your consultation will ask about pregnancy plans as part of the clinical assessment, it is a routine and important part of the conversation, not an intrusive one.
For context on how tirzepatide works as a treatment and what the full titration schedule looks like, the tirzepatide overview covers the mechanism and licensed indications in more detail. And if you are weighing up which treatment suits your situation, the weight-loss treatment overview sets out the options available through nume.
The same gastric-slowing mechanism that affects oral contraceptive absorption also applies to oral HRT. NHS England advises that women taking oral HRT alongside tirzepatide consider switching to a transdermal form (patches or gels) so that oestrogen absorption is not affected. This is a conversation to have with your GP or gynaecologist, ideally before treatment starts rather than after the first dose.
If you are using tirzepatide for blood sugar control alongside weight management, the tirzepatide and blood sugar page covers that intersection. Cost is a practical factor for many people beginning treatment; the Mounjaro pricing page explains what is included in a private prescription and how private treatment is structured.
The bottom line on contraception and tirzepatide is straightforward: if you use the pill, add a barrier method for the first four weeks and for four weeks after each dose increase, and our page on using Mounjaro with birth control covers the practical steps in full. If you use a non-oral method, no change is needed. Your prescriber confirms the right approach for your situation as part of the clinical review, and aftercare is there if questions come up later.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.